eBulletin Newsletter
NCCN Flash Updates: NCCN Guidelines Updated for Prostate Cancer
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), and the Drugs and Biologics Compendium (NCCN Compendium®) for Prostate Cancer. These NCCN Guidelines® are currently available as Version 4.2022.
Link directly to the Updates section of the NCCN Guidelines: Prostate Cancer
Updates in Version 4.2022 of the NCCN Guidelines for Prostate Cancer from Version 3.2022 include:
PROS-15
- Systemic Therapy for M1 CRPC: Adenocarcinoma
- Prior docetaxel and prior novel hormone therapy
- Added: Useful in certain circumstances
- Regimen added: Lutetium Lu 177 vipivotide tetraxetan (Lu-177–PSMA-617) for PSMA-positive metastases (category 1)
- Added: Useful in certain circumstances
- Prior docetaxel and prior novel hormone therapy
PROS-15A
- Footnote sss added: Lu-177–PSMA-617 is a treatment option for patients with ≥1 PSMA-positive lesion and/or metastatic disease that is predominately PSMA-positive and with no dominant PSMA-negative metastatic lesions who have been treated previously with androgen receptor-directed therapy and a taxane-based chemotherapy. The Panel believes that both Ga-68 PSMA-11 or F-18 piflufolastat PSMA imaging can be used to determine eligibility. Sartor et al. N Engl J Med. 2021; 385:1091-1103. See Principles of Radiation Therapy (PROS-F)
PROS-D 3 of 3
- 3rd bullet added: Synthesis of Ga-68 PSMA-11 requires that the PSMA-11 ligand is labeled with Ga-68 from a generator or cyclotron. Two commercial kits to perform this in nuclear pharmacies have been approved by the FDA.
PROS-F 5 of 6
- New section added: Lu-177-PSMA-617
MS-1
- The Discussion section has been updated to reflect changes in the algorithm.
For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.
To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.
Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.
About NCCN Flash Updates™
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content.
Subscribe to NCCN Flash Updates™
Please note: 1. Third Party Content. The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content FTP site: ftp://ftp1.nccn.org (To access: user name:content; password is NCCNcontent) (“Third Party Content”). Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works.
Access information on permissions and licensing of NCCN Content
Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.